<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03707093</url>
  </required_header>
  <id_info>
    <org_study_id>ADG106-1001</org_study_id>
    <nct_id>NCT03707093</nct_id>
  </id_info>
  <brief_title>Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Study of CD137 Agonist ADG106 Administered Intravenously in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adagene Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adagene Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, dose-escalation, multicenter study of ADG106 in subjects with&#xD;
      advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma. ADG106&#xD;
      is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb. It binds to the activated&#xD;
      human T cells via a T cell receptor CD137. T cell is a kind of lymphocyte (a subtype of white&#xD;
      blood cells) that protects bodies by eliminating tumor cells, and normal cells infected with&#xD;
      viruses or bacteria. By binding to CD137, the study drug is expected to enhance the activity&#xD;
      of activated T cells and thus stimulate a more intense immune attack to kill tumor cells.&#xD;
      ADG106 is expected to enhance the activity of activated T cells.&#xD;
&#xD;
      The primary objective of the study is to assess safety and tolerability at increasing dose&#xD;
      levels of single agent ADG106 in subjects with advanced or metastatic solid tumors and/or non&#xD;
      Hodgkin lymphoma Secondary Objectives&#xD;
&#xD;
        -  To characterize the pharmacokinetic (PK) profiles of ADG106&#xD;
&#xD;
        -  To evaluate the immunogenicity of ADG106&#xD;
&#xD;
        -  To evaluate the potential anti-tumor effect of ADG106 Exploratory Objective To identify&#xD;
           the potential biomarkers of ADG106&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing dose-limiting toxicities</measure>
    <time_frame>2 Cycles (42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing clinical and laboratory adverse events (AEs)</measure>
    <time_frame>First dose to 28 days post last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The area under the curve (AUC) of plasma concentration of drug</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum concentration (Tmax)</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest plasma concentration (C[trough])</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Solid Tumors, Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>ADG106 Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADG106</intervention_name>
    <description>IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg depending on cohort at enrollment.</description>
    <arm_group_label>ADG106 Dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Male or female, 18 years of age or older at the time of consent.&#xD;
&#xD;
          2. Provide written informed consent.&#xD;
&#xD;
          3. Subjects with advanced and/or metastatic histologically or cytologically confirmed&#xD;
             solid tumor and/or non-Hodgkin lymphoma who are refractory or relapsed from standard&#xD;
             therapy and who have exhausted all available therapies.&#xD;
&#xD;
          4. Life expectancy of 12 weeks or greater.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2.&#xD;
&#xD;
          6. At least one measurable lesion per RECIST 1.1 for solid tumors and per Lugano&#xD;
             Classification for non-Hodgkin lymphoma.&#xD;
&#xD;
          7. Adequate organ and bone marrow function&#xD;
&#xD;
          8. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             within the 7 days prior to study drug administration.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Active central nervous system primary or secondary malignancies, active seizure&#xD;
             disorder, spinal cord compression, or carcinomatous meningitis.&#xD;
&#xD;
          2. Any active autoimmune disease or documented history of autoimmune disease.&#xD;
&#xD;
          3. Infection of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis&#xD;
             C virus (HCV), except for the following:&#xD;
&#xD;
          4. History of any non-infectious hepatitis (eg, alcohol or non-alcoholic steatohepatitis,&#xD;
             drug-related or auto-immune hepatitis).&#xD;
&#xD;
          5. History of clinically significant cardiac disease.&#xD;
&#xD;
          6. Uncontrolled current illness.&#xD;
&#xD;
        8. WOCBP and sexually active fertile men with WOCBP partners who are unwilling or unable to&#xD;
        use acceptable contraception method to avoid pregnancy.&#xD;
&#xD;
        9. Women who are pregnant at Screening or prior to study drug administration. 10. Women who&#xD;
        are breastfeeding. 11. History of significant immune-mediated AE . 13. Systemic use of the&#xD;
        following therapies within 28 days prior to the first dose of study drug, or longer.&#xD;
&#xD;
        14. Subjects who got either below treatment:&#xD;
&#xD;
          -  Any previous anti-CD137 mAb (eg, utomilumab, urelumab) treatment.&#xD;
&#xD;
          -  Subject who has received allogenic hematopoietic stem cell transplant or autologous&#xD;
             stem cell transplanted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Horizon Oncology Research</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumor</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

